Proper CMC Submission -API. Ramnarayan Randad, Ph.D. DMF Review Staff/OGD June 4, 2014 GPhA/FDA Bethesda, MD
|
|
- Hillary Wilkinson
- 5 years ago
- Views:
Transcription
1 Proper CMC Submission -API Ramnarayan Randad, Ph.D. DMF Review Staff/OGD June 4, 2014 GPhA/FDA Bethesda, MD 1
2 Type II Drug Master Files (DMFs) and GDUFA Generic Drug User Fee Amendments (GDUFA) July 9, 2012 (FDASIA PDUFA, GDUFA, BsUFA). Type II DMF -one-time user fee Pass Completeness Assessment Available for Reference -Oct 2014, ww.fda.gov/gdufa DMF team pilot 2010 Affects ANDA submission Risk of causing an RTR ANDA applicant is notified ( ) of the DMF status 2
3 Completeness Assessment (CA) GDUFA requires Type II API DMFs to undergo an initial CA to ensure that the DMF is complete. Agency Guidance (10/1/2012), that include recommendation on information that should be included in the DMF. CA checklist follows CTD format: Has 62 questions DMFs that pass initial CA are published on the FDA s public Web site as available for reference ( 3
4 Format of the Checklist Administrative/General Information (question 1-11) 2.3.S QOS (question 12) 3.2.S.1 General Information (question 13-15) 3.2.S.2 Manufacture (question 16-36) 3.2.S.3 Characterization (question 37-40) 3.2.S.4 Control of Drug Substance (question 41-45) 3.2.S.5 Reference Standards or Materials (question 46-51) 3.2.S.6 Container Closure System (question 52-54) 3.2.S.7 Stability (question 55-58) 3.2 R Regional info (question 59-61) 4
5 CA Review Process DMF holder Actions DMF holder pays the DMF fee DMF holder sends notification to hhs.gov DMF holder submits amendment ANDA applicant who references this DMF FDA Actions Generate CA queue and prioritize. Issue Incomplete letter to DMF holder.* No *Notification of Incomplete status is sent to ANDA applicant if the DMF has been referenced by a submitted ANDA under filing review. Is DMF Eligible for Admin CA? No Assign to reviewer for full CA Is DMF Complete? Yes DMFs listed as available for reference on FDA website Yes 5
6 How is the Generic Industry doing with CAs? Overall Industry is adapting very well. Some metrics: DMFs for Full CA complete on the first cycle: 17% DMFs for Full CA complete by the second cycle: 88% Average response time (first cycle): 45 days CTD format and Electronic- CTD submissions greatly facilitate the process efficiency 6
7 Clarifications on DMF [Common Queries] API is a substance or a mixture when the substance is unstable or cannot be transported on its own. DMF for a mixture (e.g. API plus an excipient) can qualify as the API under GDUFA. We ask that a justification be submitted to the DMF when this claim is made. Note that these situations also have important facility fee implications. The CA requires that a DMF be for a single API produced by a single manufacturing process. 7
8 Clarifications (continued) DMF should be limited to one process although multiple manufacturing sites for a single drug process is permitted. Certain process alternatives/changes may be permissible with sufficient supportive information provided. e.g.: Validated reprocess/rework procedures Micronization leading to different particle sizes Addition of a stabilizing antioxidant for stability purpose Alternate crystallization procedure to produce a different polymorph Minor process variation that is the same chemical transformation with little risk to the impurity profile Factors which are indicative of a second process Significant process alternation resulting in different impurity profile and requiring different control strategy Different starting materials Different Intermediates 8
9 Clarifications (continued) What is the stability data requirement to pass the CA? Do the provisions of the new stability guidance apply? The guidance requirements apply to the full scientific review. To pass the CA the firm needs to demonstrate that stability studies have started (i.e. one batch with a time point beyond initial). 9
10 Policy Change for FY 2015 DMF must be Available for Reference at the time of ANDA submission or the ANDA will be Refuse to Receive For FY 2013 and 2014 this was not the case DMF holders had the entire ANDA filing window to become Available for Reference Firm s will need to coordinate DMF fee payment and ANDA submission to allow the DMF to pass the CA (we recommend 6 months) 10
11 Average time to CA Completion by Payment Month (Full CA, first cycle) Backlog > 400 Initial Bolus Cleared Backlog : 78 Backlog > Large influence of the bolus on timelines Impact was partially muted do to hiring September 2013 bolus has been cleared so another downward trend is expected # of Paid DMFs Avg Days of 1st CA Review
12 Avoid an RTR due to the DMF-Suggestions Make sure the DMF is on the Available for Reference list prior to ANDA submission Communicate with the DMF holder so they know the ANDA submission timeframe. Pay the DMF fee six-months in advance of the planned ANDA submission date This will allow sufficient time for two cycles of CA review (if needed) Submit a high-quality DMF (preferably in ectd format) 12
13 Avoid an RTR due to the DMF- Be Proactive! Know if the DMF is eligible for an administrative CA Make sure the choice of starting materials is appropriately justified For older DMFs, know whether a complete update needs to be submitte and submit ahead of payment! Make sure FDA has the current contact information (fax number) Respond to Incomplete letters as quickly as possible (30 days or less is ideal) Provide notification of amendment as instructed on the fax cover sheet! Contact us with CA status requests if the DMF is not on the list or you have not received a DMF Incomplete 13 communication (DMFOGD@FDA.HHS.GOV)
14 Resources from Oct 1, Growth in DMF Staff Since Oct 1, 2012 Oct-12 Dec-12 Feb-13 Apr-13 Jun-13 Aug-13 Oct-13 Dec-13 Feb-14 Apr-14 Large increase in resources since Oct 1, GDUFA hires in FY GDUFA hires in 2014 Total review Staff of 61 by end of 2014 Increased capability to cope with large and variable workload. Will result in much lower and predictable CA timelines
15 Thank you 15
Status Update on the Review of DMFs
Status Update on the Review of DMFs Presented by Dave Skanchy, Ph.D. Director DMF Review Staff GPhA/FDA CMC Workshop June 4, 2013 1 Outline Changes to the DMF Review Staff: Update on GDUFA hiring and the
More informationGDUFA II User Fees. Update on Implementation
GDUFA II User Fees Update on Implementation Donal Parks, Director Division of User Fee Management and Budget Formulation OM CDER US FDA November 8, 2017 Outline Refresher on GDUFA II fee structure What
More informationCompleteness Assessments for Type II API DMFs Under GDUFA Guidance for Industry
Completeness Assessments for Type II API DMFs Under GDUFA Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
More informationGDUFA: 2 ½ years later Impact & Importance
GDUFA: 2 ½ years later Impact & Importance Georgia Hizon Manager, Regulatory Publications Fresenius Kabi USA, LLC Disclaimer The views and opinions expressed in the following PowerPoint slides are those
More informationANDA Filing and Refuse to Receive Issues. Johnny Young, M.A.L.A.
ANDA Filing and Refuse to Receive Issues Johnny Young, M.A.L.A. 1 Statistics 2 497 ANDAs Refused-for-Receipt between CYs 2009-2012: - 12% (2009) - 18% (2010) - 15.5% (2011) - 9.4% (2012) 3 For 2012, 100
More informationANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry
ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More informationGuidance for Industry ANDA Submissions Refuse-to-Receive Standards
Guidance for Industry ANDA Submissions Refuse-to-Receive Standards DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
More informationGeneric Drug User Fee Amendments of 2012; Regulatory Science Initiatives; Public Hearing;
4160-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Part 15 [Docket No. FDA-2013-N-0402] Generic Drug User Fee Amendments of 2012; Regulatory Science Initiatives; Public
More informationOFFICE OF PHARMACEUTICAL SCIENCES. COVER FORM FOR THE TECHNICAL REVIEW OF DRUG MASTER FILES (DMFs) CONTENTS
MANUAL OF POLICIES AND PROCEDURES CENTER FOR DRUG EVALUATION AND RESEARCH MAPP 5015.3 OFFICE OF PHARMACEUTICAL SCIENCES COVER FORM FOR THE TECHNICAL REVIEW OF DRUG MASTER FILES (DMFs) CONTENTS PURPOSE
More information510(k) submissions. Getting US FDA clearance for your device: Improving
Getting US FDA clearance for your device: Improving 510(k) submissions Audrey Swearingen, RAC Director, Regulatory Affairs Telephone: +1 512.222.0263 Email: aswearingen@emergogroup.com Download this white
More informationCancer Immunotherapy Pilot Program/ Patents 4 Patients. USPTO BCP Customer Partnership Meeting Alexandria, VA August 2, 2017
Cancer Immunotherapy Pilot Program/ Patents 4 Patients USPTO BCP Customer Partnership Meeting Alexandria, VA August 2, 2017 1 Cancer Immunotherapy Pilot Program/ Patents 4 Patients The United States Patent
More informationTexas Vendor Drug Program Specialty Drug List Process. February 2019
Texas Vendor Drug Program Specialty Drug List Process February 2019 Table of Contents Table of Contents...1 1 About the Specialty Drug List...2 1.1 Information for Pharmacies... 2 1.2 Information for Managed
More informationOffice of Generic Drugs. April 14, 2010
Considerations for PET ANDAs Office of Generic Drugs April 14, 2010 1 Agenda Office of Generic Drugs: background information RLDs and Suitability Petitions Submission requirements for an ANDA Approval
More informationGuideline on influenza vaccines submission and procedural requirements
1 2 3 October 2014 EMA/56793/2014 Human Medicines Research and Development Support 4 5 6 Guideline on influenza vaccines submission and procedural requirements Regulatory and procedural requirements module
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
SOP details SOP title: SOP number: SOP category: Version number: 03 Version date: 19 December 2016 Effective date: 19 January 2017 Revision due date: 19 January 2020 NEWCASTLE CLINICAL TRIALS UNIT STANDARD
More informationAutism Funding Programs
Autism Funding Programs A Guide to Invoice Payment Forms Why is Autism Funding Provided? The primary intent of Autism Funding is to assist families with the cost of purchasing autism intervention that
More informationTeva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs 425 Privet Road Horsham, PA 19044
DEPARTMENT OF HEALTH & HUMAN SERVICES ANDA 090783 Food and Drug Administration Silver Spring, MD 20993 Teva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs
More informationCLIENT PROCEDURE FOR ANNUAL APPROVAL OF SHIP REPAIR COMPANIES
CLIENT PROCEDURE FOR ANNUAL APPROVAL OF SHIP REPAIR COMPANIES 1.0 PURPOSE Safe work environment is essential for performing all kinds of ship repair operations. In this regard and to enable safe and smooth
More informationMEAT CONTENT CALCULATION
MEAT CONTENT CALCULATION Introduction Amendments to the European Labelling Directive have resulted in the need to harmonise the definition of meat across Europe. This new definition attempts to ensure
More informationGet Instant Access to ebook Anda Checklist PDF at Our Huge Library ANDA CHECKLIST PDF. ==> Download: ANDA CHECKLIST PDF
ANDA CHECKLIST PDF ==> Download: ANDA CHECKLIST PDF ANDA CHECKLIST PDF - Are you searching for Anda Checklist Books? Now, you will be happy that at this time Anda Checklist PDF is available at our online
More informationMedical Necessity and the Retrospective Review Process
Medical Necessity and the Retrospective Review Process Medicaid Retrospective Therapy Review Medicaid contracted with QSource of Arkansas to perform post-payment audits Random quarterly selection across
More informationGuide to Interchangeable Medicines
Guide to Interchangeable Medicines AUT-G0115-6 01 JUNE 2018 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS 1 BACKGROUND 3 1.1
More informationOverview of Regulatory Science of Food Contact Substances
Overview of Regulatory Science of Food Contact Substances Michael A. Adams, PhD Deputy Director, Office of Food Additive Safety FDA, Center for Food Safety and Applied Nutrition 5001 Campus Drive, College
More informationProcedural advice on the submission of variations for annual update of human influenza inactivated vaccines applications in the centralised procedure
1 2 3 4 5 6 7 8 9 14 April 2010 EMA/CHMP/BWP/99698/2007 Rev. 1 Committee for Medicinal Products for Human Use (CHMP) Procedural advice on the submission of variations for annual update of human influenza
More informationCriteria and Application for Men
Criteria and Application for Men Return completed form via fax or email to LIVESTRONG Foundation attn LIVESTRONG Fertility Fax 512.309.5515 email Cancer.Navigation@LIVESTRONG.org Made possible by participating
More informationPart D PDE Data and the Opioid Epidemic
Part D PDE Data and the Opioid Epidemic State Data Resource Center Acumen, LLC August 30, 2017 3:30-4:30pm ET Outline Background Information on Opioid Use Helpful Part D Elements for Analysis How to Perform
More informationTaking Part B Therapy Beyond the $3,700 Threshold New Manual Medical Review Process Effective date October 1, 2012
Taking Part B Therapy Beyond the $3,700 Threshold New Manual Medical Review Process Effective date October 1, 2012 Presented by: Leigh Ann Frick, PT, MBA Vice President of Clinical Services Heritage Healthcare
More informationGuideline on the Regulation of Therapeutic Products in New Zealand
Guideline on the Regulation of Therapeutic Products in New Zealand Part 10: Requirements for information for prescribers and consumers Edition 7.0 January 2016 Section 1: Legislation Section summary This
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL GUIDELINES and FORMS TABLE OF CONTENTS 1 Guidelines and Forms 1.01 Index to Guidelines and Forms 2 Human Medicines 2.01 General information 2.02 Pharmaceutical and Analytical
More informationSection VII: HIV/AIDS & STD. MPR 1 Provide and/or refer clients for HIV and STD screening and treatment, regardless of client ability to pay.
All Minimum Program Requirements (MPRs) and Indicators listed below are required for the agency to meet in order to pass the HIV/AIDS and STD section of the Accreditation Review. Sources of authority:
More informationResearch on the Administrative Rules of APIs, Pharmaceutical Excipients and Auxiliary Materials Master File. Translation version
Research on the Administrative Rules of APIs, Pharmaceutical Excipients and Auxiliary Materials Master File Division of Pharmaceuticals Department of Drug Registration Hou Renping Translation version Main
More information2010 Sharing Hope Program for men
2010 Sharing Hope Program for men Criteria and Application Made possible by participating sperm banks and fertility centers Program Overview Goal Cancer patients have little opportunity to save for the
More informationMHRA Pharmacovigilance Inspections: Prepare and Manage for Success
MHRA Pharmacovigilance Inspections: Prepare and Manage for Success Created and Presented by Miranda Dollen Vice President, Pharmacovigilance & EEA QPPV Mapi 2016, All Rights Reserved 2 Prepare and Manage
More informationConsultant-led Referral to Treatment (RTT) waiting times collection timetable: outcome of consultation
Consultant-led Referral to Treatment (RTT) waiting times collection timetable: outcome of consultation Summary Between January and March 2014, NHS England consulted on a proposed change to the timetable
More informationMcLean ebasis plus TM
McLean ebasis plus TM Sample Hospital (0000) Report For Qtr HBIPS Core Measures McLean Hospital 115 Mill Street Belmont, MA 02478 1 2012 Department of Mental Health Services Evaluation Tel: 617-855-3797
More informationInpatient Psychiatric Facility Quality Reporting (IPFQR) Program
FY 2017 IPPS Final Rule IPFQR Changes, APU Determination and Reconsideration Review Questions and Answers Moderator/Speaker: Evette Robinson, MPH Project Lead, IPFQR Inpatient Hospital Value, Incentives,
More informationCDER Compliance Update
CDER Compliance Update Douglas Stearn, JD Deputy Director for Policy and Analysis FDA/CDER/Office of Compliance FDLI Enforcement, Litigation and Compliance Conference Washington, DC December 12, 2012 1
More informationOncology Solutions Provider Training Program. Horizon NJ Health
Oncology Solutions Provider Training Program Horizon NJ Health NIA Training Program NIA A Magellan Health Company 2 NIA Program Agenda Introduction to the Training Our Program 1. Authorization Process
More informationINFORMATION FOR RESEARCHERS REQUESTING DATA FROM THE NHVPR
INFORMATION FOR RESEARCHERS REQUESTING DATA FROM THE NHVPR What is the NHVPR? The National Human Papillomavirus Vaccination Program Register (NHVPR) is the Australian register which records HPV vaccine
More informationPreparing a US FDA Medical Device 510(K) Submission
Preparing a US FDA Medical Device 510(K) Submission If you want to introduce your medical device to the US market, you need to obtain clearance from the FDA. This clearance is obtained from the FDA via
More informationParametric Release Regulatory Requirements. Terry E. Munson Technical Vice President PAREXEL International, LLC
Parametric Release Regulatory Requirements Terry E. Munson Technical Vice President History First application approved for parametric release in 1985 Formed the basis for the FDA Compliance Policy Guide
More informationUSDA Demonstration Project for Non-Congregate Feeding for Outdoor Summer Meal Sites Experiencing Excessive Heat
SUMMER FOOD SERVICE PROGRAM CLARIFICATION OF FEDERAL POLICY In Texas, organizations contracting directly with the (TDA) to operate nutrition programs federally funded through the United States Department
More informationEnhanced service specification Childhood seasonal influenza vaccination programme NHS England gateway reference: 01641
Enhanced service specification Childhood seasonal influenza vaccination programme NHS England gateway reference: 01641 Introduction 1. All GMS practices are expected to provide essential and those additional
More informationGuideline on the processing of renewals in the centralised procedure
14 July 2016 Committee for Human Medicinal Products (CHMP) Guideline on the processing of renewals in the centralised procedure Transmission to CPMP November 2000 Release for consultation December 2000
More informationProcedure for Registration / Renewal of Third Party Hazmat/Industrial Tank Cleaning Contractors
Procedure for Registration / Renewal of Third Party Hazmat/Industrial Tank Cleaning Contractors 1. PURPOSE: The competency and integrity of the 3 rd party Hazmat/ Industrial Tank Cleaning contractors are
More informationThe American College of Radiology Breast Ultrasound Accreditation Program: Frequently Asked Questions (Revised: July 31, 2017)
The American College of Radiology Breast Ultrasound Accreditation Program: Frequently Asked Questions (Revised: July 31, 2017) Table of Contents APPLICATION - GENERAL... 1 MOVED FACILITIES AND UNITS...
More informationRisk-Based CMC ANDA Review
Risk-Based CMC ANDA Review Andre Raw*, PhD Director Division of Chemistry I FDA-CDER- Office of Generic Drugs andre.raw@fda.hhs.gov *This presentation reflects the views of the author and should not be
More informationSport and Exercise Science Undergraduate Practicum Application Packet Instructions
Sport and Exercise Science Undergraduate Practicum Application Packet Instructions Please read the ENTIRE instructions and information sheets carefully for complete directions and information before completing
More informationFeidhmeannacht na Seirbhíse Sláinte
Feidhmeannacht na Seirbhíse Sláinte Health Service Executive TITLE FORENAME SURNAME ADDRESS 1 ADDRESS 2 ADDRESS 3 COUNTY Feidhmeannacht na Seirbhíse Sláinte Seirbhís Aisíoca Príomhchúraim Bealach amach
More informationHarvard Pilgrim Spine Management Provider Training
Harvard Pilgrim Spine Management Provider Training NIA Training Program 2 NIA Program Agenda Our Program 1. Authorization Process 2. Other Program Components 3. Provider Tools and Contact Information RadMD
More informationPre-Claim Review Demonstration for Home Health Services in IL. Implementation Workshop Series
Pre-Claim Review Demonstration for Home Health Services in IL Implementation Workshop Series Disclaimer The information enclosed was current at the time i t was presented. Medicare policy changes frequently;
More informationRPL Form Diploma of Remedial Massage HLT50307
Please read the information below and complete all sections of this form. RPL Form Diploma of Remedial Massage HLT50307 Recognition of Prior Learning (RPL) ACFB provides a simple process in gaining Recognition
More information(In chronological order, provide work, volunteer, community service information after earning your initial dental degree)
NOTE For the Dental Curriculum Vitae (CV), provide information on your educational credentials and dental experience starting after your initial dental degree. Please classify your dental experience by
More informationPublic Policy HCA Public Policy No
Public Policy HCA Public Policy No.11-2016 TO: FROM: RE: HCA HOSPICE PROVIDER MEMBERS PATRICK CONOLE, VICE PRESIDENT, FINANCE & MANAGEMENT UPDATES FROM NGS HOSPICE ADVISORY MEETING DATE: JUNE 10, 2016
More informationUpdate on CDER s Drug Development Tool Qualification Program
Update on CDER s Drug Development Tool Qualification Program ShaAvhree Buckman-Garner, M.D., Ph.D. Director Office of Translational Sciences Center for Drug Evaluation and Research U.S. Food and Drug Administration
More informationNew Drugs Division. Frequently Asked Questions (FAQs) on Approval of new Phytopharmaceutical Drugs
Central Drugs Standard Control Organization Directorate General of Health Services Ministry of Health and Family Welfare Government of India New Drugs Division Frequently Asked Questions (FAQs) on Approval
More informationNIA Magellan 1 Radiation Oncology Solution Provider Training
NIA Magellan 1 Radiation Oncology Solution Provider Training Provider Training Program 1 - NIA Magellan refers to National Imaging Associates, Inc. NIA Magellan Training Program 2 NIA Magellan Program
More informationCHAPTER 7 SECTION 24.1 PHASE I, PHASE II, AND PHASE III CANCER CLINICAL TRIALS TRICARE POLICY MANUAL M, AUGUST 1, 2002 MEDICINE
MEDICINE CHAPTER 7 SECTION 24.1 ISSUE DATE: AUTHORITY: 32 CFR 199.4(e)(26) I. DESCRIPTION The Department of Defense (DoD) Cancer Prevention and Treatment Clinical Trials Demonstration was conducted from
More informationMartin Shimer Deputy Director, Division of Legal and Regulatory Support Office of Generic Drug Policy
M E M O R A N D U M DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH DATE: November 9, 2017 FROM: Martin Shimer Deputy
More informationAppendix C NEWBORN HEARING SCREENING PROJECT
Appendix C NEWBORN HEARING SCREENING PROJECT I. WEST VIRGINIA STATE LAW All newborns born in the State of West Virginia must be screened for hearing impairment as required in WV Code 16-22A and 16-1-7,
More informationMaster Files with ectd
Master Files with ectd Follow-up Information Meeting Step 2 Dr. Christoph Berger August 31, 2010 Swissmedic Schweizerisches Heilmittelinstitut Hallerstrasse 7 CH-3000 Bern www.swissmedic.ch Overview 1.
More informationin the ICH Regions Table of Content Annexes to Guideline and 3. Why is Q4B necessary? Q4B Annexes? for Human Use
Frequently Asked Questions Q4B: Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions The Q4B Expert Working Group developed a set of frequently asked questions to help users
More informationMy VeriSTAR & Veristar Info: The all-in-one portal for Marine professionals
My VeriSTAR & Veristar Info: The all-in-one portal for Marine professionals My VeriSTAR mobile application Veristar Info website Monitor your fleet Plan your surveys Stay informed, anytime, anywhere Manage
More informationCERTIFICATION IN LOWER EXTREMITY GERIATRIC MEDICINE CASE REQUIREMENTS AND GUIDELINES
CERTIFICATION IN LOWER EXTREMITY GERIATRIC MEDICINE CASE REQUIREMENTS AND GUIDELINES 555 8 th Ave Suite 1902 New York, NY 10018 (888) 852-1442 Document number: 61714.10142017 Originated 10.14.2017 ABMSP
More informationPractical guidance for applicants on the submission of applications on food additives, food enzymes and food flavourings
Version 2 Updated on 29/11/2011 Practical guidance for applicants on the submission of applications on food additives, food enzymes and food flavourings Valid as of: 11 September 2011 Disclaimer: This
More informationREGULATORY REQUIREMENTS FOR REGISTRATION OF HEALTH SUPPLEMENTS IN MALAYSIA
REGULATORY REQUIREMENTS FOR REGISTRATION OF HEALTH SUPPLEMENTS IN MALAYSIA TAN JAS MIN National Pharmaceutical Regulatory Agency Ministry of Health Malaysia Email address: tanjasmin@npra.gov.my ORGANISATION
More informationRAPID Meeting. February 2018
RAPID Meeting February 2018 Agenda 2017 Annual Inspection Results and 2018 Priorities InfoEd Updates Refrigerator and Freezer Monitoring Program Lessons Learned Program New EHS Customer Satisfaction Survey
More informationCamp SOCIAL Malden Higher Education Center 700 N. Douglass Street Malden, MO Camp Tuition: PAID by SE PAC* Ages Divided in Groups
A Social Cognition Camp for Youth with HFA Sponsored by Southeast Missouri Autism Project Parent Advisory Committee SESSION 1 Dates: June 6-10, 2016 Monday through Friday 8:30 am to Noon All Camp Activities
More informationFrequently Asked Questions
Frequently Asked Questions These were updated on March 2018. 1. Details of revised Scheme from 4 April 2018 We are retaining the higher level of award ( 1,000) for childminders who care for children with
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Burzynski Research Institute
More informationSIS Solution Update. Thierry Cerpolet Senior Manager, Business Solutions and Systems Development IATA. Agenda
SIS Solution Update Thierry Cerpolet Senior Manager, Business Solutions and Systems Development IATA WFS 2017 Industry Meetings SIS Usage and Performance SIS Major Releases Evolution SIS Infrastructure
More informationUNIT MITIGATION REQUEST FOR CONSIDERATION PROCESS
What is a mitigating factor? A mitigating factor is a significant occurrence beyond a unit s control that triggers a measurable impact not only on the NPA composite summary, but on the Pay for Performance
More informationHOSPICE INFORMATION FOR MEDICARE PART D PLANS
HOSPICE INFORMATION FOR MEDICARE PART D PLANS SECTION I -HOSPICE INFORMATION TO OVERRIDE AN HOSPICE A3 REJECT OR TO UPDATE HOSPICE STATUS A. Purpose of the form (please check all appropriate boxes) : Admission
More informationCONSOLIDATED EDISON COMPANY OF NEW YORK, INC. 4 IRVING PLACE NEW YORK, NY 10003
CONSOLIDATED EDISON COMPANY OF NEW YORK, INC. 4 IRVING PLACE NEW YORK, NY 003 ENERGY EFFICIENCY AND DEMAND MANAGEMENT DEPARTMENT COMMERCIAL CUSTOMER SOLUTIONS SECTION SPECIFICATION EE-CS- REVISION 00 EFFECTIVE
More informationResults from the NAQC annual survey of quitlines, FY17
Results from the NAQC annual survey of quitlines, FY17 We will start at 3:00pm ET To mute your line: *1 To unmute your line: *1 For operator assistance: *0 Please do not put your line on hold Results from
More informationURGENT MEDICAL DEVICE CORRECTION. Important Information about Animas 2020, IR 1250 or IR 1200 Insulin Pumps
URGENT MEDICAL DEVICE CORRECTION May 26, 2015 Important Information about Animas 2020, IR 1250 or IR 1200 Insulin Pumps Dear Healthcare Professional: At Animas, we hold our products to the highest standards
More informationOutpatient Quality Reporting Program
Abstraction Tricks and Tips Questions & Answers Moderator: Nina Rose, MA Project Coordinator/HSAG Speaker(s): Karen VanBourgondien, RN, BSN Education Coordinator/HSAG June 17, 2015 10:00 a.m. Question
More informationAmerican Emu Association. Certified Emu Oil Program
Table of Contents Part 1. Frequently Asked Questions... 3 Part 2. AEA Certified Fully Refined Seal & Verbiage Usage Requirements... 5 Section A. Program Requirements... 5 Section B. Product Labeling Requirements...
More informationNews & Views. Antipsychotics on Maryland Medicaid PDL and Coverage of a 30-day Emergency Supply of Atypical Antipsychotics
Maryland Medicaid Pharmacy Program News & Views February 2011 Maryland Department of Health and Mental Hygiene /Office of Systems, Operations and Pharmacy Antipsychotics on Maryland Medicaid PDL and Coverage
More informationNYS Paid Family Leave (PFL) Q & A 5/10/18
NYS Paid Family Leave (PFL) Q & A 5/10/18 Question 1: Question 2: What is NYS Paid Family Leave (PFL)? NYS Paid Family Leave will provide eligible workers with wage replacement during time away from work
More informationInternational Emergency and Expatriate Dental Program Instructions For Dentists
International Emergency and Expatriate Dental Program Instructions For Dentists DeCare Dental is a leading dental benefit management company, serving a variety of dental benefit brand names across the
More information4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP
New Mexico s Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy New Mexico and the PMP In 2012, New Mexico had the 3 nd Highest Overdose Death Rate in Nation.! 492 Deaths or a rate of 23.6
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 6 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations P.A. Benjamin Manufacturing
More informationAn Epic Battle Pharmacist Heroes vs. Shortages
An Epic Battle Pharmacist Heroes vs. Shortages Erin R. Fox, PharmD, BCPS, FASHP Twitter: @foxerinr mmpharmd Disclosure This presentation represents my own opinions. University of Utah Drug Information
More informationImportant Information about your 2.0 ml Animas Insulin Pump Cartridges
URGENT: INSULIN PUMP 2.0 ml CARTRIDGE RECALL February 24, 2011 Dear Animas Pumper: Important Information about your 2.0 ml Animas Insulin Pump Cartridges Animas Corporation is dedicated to supporting pumpers
More informationAnalysis of State Medicaid Agency Performance in Relation to Incentivizing the Provision of H1N1 Immunizations to Eligible Populations
Analysis of State Medicaid Agency Performance in Relation to Incentivizing the Provision of H1N1 Immunizations to Eligible Populations Nancy Lopez, JD, MPH, Ross Margulies, JD/MPH [Cand.], and Sara Rosenbaum,
More informationEHR Developer Code of Conduct Frequently Asked Questions
EHR Developer Code of Conduct Frequently Asked Questions General What is the purpose of the EHR Developer Code of Conduct? EHR Association (the Association) members have a long tradition of working with
More informationDry Needling (DN) Registration
Dry Needling (DN) Registration To register for any of our programs, please complete the enclosed registration form (next page) and mail of fax the form to us. Fees Cost of the DN 1-3 courses is US $895
More informationState of Connecticut Department of Education Division of Teaching and Learning Programs and Services Bureau of Special Education
State of Connecticut Department of Education Division of Teaching and Learning Programs and Services Bureau of Special Education Introduction Steps to Protect a Child s Right to Special Education: Procedural
More informationGuidance on Drug Master File System in Japan
2 nd China Japan Symposium on Drug Development focusing on IND, Pre Consultation, ti GMP and DMF System March 29, 2011 in Beijing Guidance on Drug Master File System in Japan Takashi YOSHITANI, Ph.D. Master
More informationChapter 18 Section 2. EXPIRED - Department Of Defense (DoD) Cancer Prevention And Treatment Clinical Trials Demonstration
s And Pilot Projects Chapter 18 Section 2 EXPIRED - Department Of Defense (DoD) Cancer Prevention And Treatment Clinical Trials 1.0 PURPOSE The purpose of this demonstration is to improve TRICARE-eligible
More informationFrequently Asked Questions
Frequently Asked Questions (Updated November 2018.) The Department for Education has taken the decision to end the Childcare Business Grant Scheme (CBGS) from 31 March 2019. This is based largely on a
More informationProfessional CGM Reimbursement Guide
Professional CGM Reimbursement Guide 2015 TABLE OF CONTENTS Coding, Coverage and Payment...2 Coding and Billing...2 CPT Code 95250...3 CPT Code 95251...3 Incident to Billing for Physicians..............................................
More informationCertified Peer Specialist Training Application
Please read the CPS Application Supplement before completing application. Go to http://www.viahope.org/resources/peer-specialist-training-application-supplement This training is intended for individuals
More informationWhat's Important to Consider When Developing a Complex Generic Drug? September 5, 2018
What's Important to Consider When Developing a Complex Generic Drug? September 5, 2018 Session Description FDA has provided drug manufacturers tools to assist the development of complex generic drugs to
More informationPrimer: Medical Device User Fee Amendments Han Zhong l September 2011
Primer: Medical Device User Fee Amendments Han Zhong l September 2011 Introduction The Medical Device User Fee and Modernization Act (MDUFMA or MDUFA) is a set of agreements between the Food and Drug Administration
More informationLactose, Monohydrate
Lactose, Monohydrate Product Regulatory Data Sheet Section 1 Product Information Products Covered Brand Product Code Product Description MOC Code J.T.Baker 2249 Lactose, Monohydrate, Powder N.F. R J.T.Baker
More informationFREQUENTLY ASKED QUESTIONS
FREQUENTLY ASKED QUESTIONS Since the implementation of the Safe and Sacred program, the Office of Safe Environment Programs has received some questions from our users about the program and the background
More informationFertility Center and Sperm Bank Manual for the Fertile Hope Program for Men
Fertility Center and Sperm Bank Manual for the Fertile Hope Program for Men Table of Contents I. Fertile Hope Program for Men: An Overview...3 II. Referring to the Fertile Hope Program in Your Publications.3
More informationLiposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation
Liposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation Guidance for Industry U.S. Department of Health and Human Services
More information